FDA Approves Genentech’s Phesgo (Fixed-dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-positive Breast Cancer -…
Posted: July 1, 2020 at 12:42 pm
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo, a fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC, under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Genentech has combined two monoclonal antibodies that can be administered by a single SC injection.
The FDA approval of Phesgo reflects our commitment to improving outcomes for the many people living with HER2-positive breast cancer, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. Phesgo offers a treatment administration that supports the needs and preferences of individual patients, and helps to meet the increasing demand across the healthcare system for faster and more flexible treatment options.
Phesgo is available in one single-dose vial. Administration can take approximately eight minutes for the initial loading dose and approximately five minutes for each subsequent maintenance dose. This is compared to approximately 150 minutes for infusion of a loading dose of Perjeta and Herceptin using the standard IV formulations, and between 60-150 minutes for subsequent maintenance infusions of the two medicines. Phesgo can be administered by a healthcare professional in a treatment center or at a patients home.
The approval is based on results from the pivotal Phase III FeDeriCa study, which met its primary endpoint with Phesgo showing non-inferior levels of Perjeta in the blood during a given dosing interval (Ctrough) when compared to IV administration of Perjeta. The safety profile of Phesgo with chemotherapy was comparable to IV administration of Perjeta plus Herceptin and chemotherapy, and no new safety signals were identified, including no meaningful difference in cardiac toxicity. The most common adverse events in both arms were alopecia, nausea, diarrhea and anemia.
The Phase II PHranceSCa study showed that 85% (136/160) of people receiving treatment for HER2-positive breast cancer preferred treatment under the skin to IV administration due to less time in the clinic and more comfortable treatment administration.
For those who qualify, Genentech will offer patient assistance programs for people prescribed Phesgo by their doctor through Genentech Access Solutions. Please contact Genentech Access Solutions at (866) 422-2377 or visit http://www.Genentech-Access.com for more information.
About the FeDeriCa study
FeDeriCa is an international, multi-center, two-arm, randomized, open-label, Phase III study evaluating the pharmacokinetics, efficacy, and safety of SC injection of Phesgo in combination with chemotherapy, compared with standard IV infusion of Perjeta and Herceptin in combination with chemotherapy, in 500 people with HER2-positive EBC who are being treated in the neoadjuvant (before surgery) and adjuvant (after surgery) settings. The primary endpoint of the study is minimum levels of Perjeta in the blood during a given dosing interval (Ctrough). Secondary endpoints include safety; minimum levels of Herceptin in the blood during a given dosing interval (Ctrough); and total pathological complete response, meaning there is no tumor tissue detectable in the tissue removed at the time of surgery. The safety profile of Phesgo was comparable with that of Perjeta and Herceptin administered intravenously.
Data from the FeDeriCa study were presented at the San Antonio Breast Cancer Symposium in December 2019. The FeDeriCa study met its primary endpoint of non-inferior levels of Perjeta in the blood. The geometric mean ratio (GMR; a type of average used when assessing pharmacokinetics) for the primary endpoint was 1.22 (90% CI: 1.14 to 1.31), with the lower limit of the 90% CI of the GMR=1.140.80 (the pre-specified non-inferiority margin). A secondary endpoint of non-inferior levels of Herceptin was also met, with blood concentrations for people receiving the fixed-dose combination non-inferior to those receiving IV Herceptin (GMR=1.33 [90% CI: 1.24 to 1.43]; lower limit of 90% CI of GMR=1.240.80). A non-inferiority endpoint was chosen for the study to ensure that people were receiving sufficient dosing with Perjeta and Herceptin as compared to the established IV doses at the same treatment intervals.
About the PHranceSCa study
PHranceSCa is a randomized, multi-center, multinational, open-label, cross-over Phase II study evaluating patient preference for and satisfaction with subcutaneous (SC) administration of Phesgo. All patients completed neoadjuvant treatment with Perjeta, Herceptin and chemotherapy and had surgery before randomization. The primary endpoint of the study is the percentage of participants who indicate that they prefer treatment with Phesgo compared to the standard intravenous (IV) formulations of Perjeta and Herceptin. Secondary endpoints include participant-reported satisfaction and health-related quality of life outcomes; healthcare professionals' perceptions of time and resource use and convenience compared with IV formulations; as well as the safety and efficacy of each study regimen.
About HER2-positive breast cancer
Breast cancer is one of the most common cancers among women worldwide. According to the American Cancer Society, close to 280,000 people in the United States will be diagnosed with breast cancer, and more than 42,000 will die from the disease in 2020. Breast cancer is not one, but many diseases based on the biology of each tumor. In HER2-positive breast cancer, there is excess HER2 protein on the surface of tumor cells. Approximately 15-20% of breast cancers are HER2-positive based on the result of a diagnostic test.
About Phesgo
Phesgo (subcutaneous Perjeta and Herceptin) is a new fixed-dose formulation of Perjeta and Herceptin with Halozyme Therapeutics Enhanze drug delivery technology.
Trastuzumab in Phesgo is the same monoclonal antibody as in IV Herceptin and pertuzumab in Phesgo is the same monoclonal antibody as in IV Perjeta. The mechanisms of action of Perjeta and Herceptin are believed to complement each other, as both bind to the HER2 receptor, but to different places. The combination of Perjeta and Herceptin is thought to provide a more comprehensive, dual blockade of HER signaling pathways, thus preventing tumor cell growth and survival.
Halozymes Enhanze drug delivery technology may enable and optimize SC drug delivery for appropriate co-administered therapeutics. The technology is based on a proprietary recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily degrades hyaluronan a glycosaminoglycan or chain of natural sugars in the body, to aid in the dispersion and absorption of other injected therapeutic drugs.
Phesgo Indications and Important Safety Information
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:
Phesgo is also approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
Important Safety Information
What should patients know about side effects with Phesgo?
Most serious side effects with Phesgo
Phesgo may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
Receiving Phesgo during pregnancy can result in the death of an unborn baby and birth defects.
Phesgo may cause serious lung problems.
Who should not receive Phesgo?
Other possible serious side effects
Most common side effects
The most common side effects of Phesgo when given with chemotherapy as part of an early breast cancer regimen are:
The most common side effects of Phesgo when given with docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
Patients are encouraged to report side effects to Genentech and the FDA. Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at 1-888-835-2555.
Patients should talk to a healthcare professional for more information about the benefits and risks of Phesgo.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If a patient cannot afford their medication, visit http://www.genentech-access.com/patient for financial assistance information.
About Expanded Access Treatment Protocol for Continuity of Care During COVID-19
Genentech launched an expanded access treatment protocol in the United States, where the FDC of Perjeta and Herceptin is administered at home by a home health nursing provider. The study will continue beyond approval, aiming to help continuity of care during the COVID-19 pandemic for certain patients with HER2-positive breast cancer who have completed chemotherapy concurrent with Perjeta and Herceptin intravenously and are currently receiving or will be receiving Perjeta and Herceptin alone. To learn more, please visit here.
About Genentech Access Solutions
Access Solutions is part of Genentechs commitment to helping people access the Genentech medicines they are prescribed, regardless of their ability to pay. The team of in-house specialists at Access Solutions is dedicated to helping people navigate the access and reimbursement process, and to providing assistance to eligible patients in the United States who are uninsured or cannot afford the out-of-pocket costs for their medicine. To date, the team has helped more than 2 million patients access the medicines they need. Please contact Access Solutions (866) 4ACCESS/(866) 422-2377 or visit http://www.Genentech-Access.com for more information.
About Genentech in breast cancer
Genentech has been advancing breast cancer research for more than 30 years with the goal of helping as many people with the disease as possible. Our medicines, along with companion diagnostic tests, have substantially improved outcomes for HER2-positive breast cancer. As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for other subtypes of the disease, including triple-negative and hormone receptor-positive.
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005687/en/
Follow this link:
FDA Approves Genentech's Phesgo (Fixed-dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-positive Breast Cancer -...
- Gene Therapy | Doctor | Patient.co.uk [Last Updated On: May 23rd, 2015] [Originally Added On: May 23rd, 2015]
- Gene Therapy | Doctor | Patient [Last Updated On: June 9th, 2015] [Originally Added On: June 9th, 2015]
- Dr Rajiv Desai Blog Archive GENE THERAPY [Last Updated On: August 23rd, 2015] [Originally Added On: August 23rd, 2015]
- Local Doctor Leads Study Of Gene Therapy Treatment For ... [Last Updated On: March 19th, 2016] [Originally Added On: March 19th, 2016]
- Breast Cancer Risk Factors: Genetics [Last Updated On: August 24th, 2016] [Originally Added On: August 24th, 2016]
- Worlds Leading Biomarkers Congress | CPD Points ... [Last Updated On: September 22nd, 2016] [Originally Added On: September 22nd, 2016]
- Why the super-rich are ploughing billions into the booming 'immortality industry' - Evening Standard [Last Updated On: July 1st, 2017] [Originally Added On: July 1st, 2017]
- What to Know About Charlie Gard, the Terminally Ill Baby Trump Wants to Help - TIME [Last Updated On: July 4th, 2017] [Originally Added On: July 4th, 2017]
- Cancer treatment is swiftly moving toward individualized molecular and genetic tools that Sparrow Cancer Center's ... - City Pulse [Last Updated On: July 7th, 2017] [Originally Added On: July 7th, 2017]
- Tumor gene testing urged to tell if drug targets your cancer - ABC News [Last Updated On: July 7th, 2017] [Originally Added On: July 7th, 2017]
- Tumor gene testing urged to tell if drug targets your cancer | KRQE ... - KRQE News 13 [Last Updated On: July 8th, 2017] [Originally Added On: July 8th, 2017]
- Tumor gene testing urged to tell if drug targets your cancer - The ... - The Mainichi [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- Charlie Gard: Medical experts weigh in on case of terminally-ill baby - The Independent [Last Updated On: July 10th, 2017] [Originally Added On: July 10th, 2017]
- High-tech solutions top the list in the fight against eye disease - Engadget [Last Updated On: July 12th, 2017] [Originally Added On: July 12th, 2017]
- 'Prehab' therapy helps cancer patients prepare for treatment - KTBS [Last Updated On: July 12th, 2017] [Originally Added On: July 12th, 2017]
- Baby Charlie remains on life support as parents fight doctors for experimental treatment - CBC.ca [Last Updated On: July 13th, 2017] [Originally Added On: July 13th, 2017]
- Novel cancer treatment wins endorsement of FDA advisers - Washington Post [Last Updated On: July 13th, 2017] [Originally Added On: July 13th, 2017]
- Ocean Springs parents fight to save 3-year-old daughter from fatal genetic condition - WGNO [Last Updated On: July 31st, 2017] [Originally Added On: July 31st, 2017]
- US doctor who wanted to treat Charlie Gard had 'financial interest' says Great Ormond Street - Metro [Last Updated On: July 31st, 2017] [Originally Added On: July 31st, 2017]
- New cancer therapy in clinical trial at Nebraska Medical Center has ... - Omaha World-Herald [Last Updated On: August 1st, 2017] [Originally Added On: August 1st, 2017]
- Scientists successfully doctor human embroyo - Examiner Enterprise [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- WBZ-TV Riders Take On Pan-Mass Challenge - CBS Boston / WBZ [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- Gene editing breakthrough: Perspective from a geneticist and a pastor - WTSP 10 News [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- Indian-origin doctor helps gene editing of human embryos - Times of India [Last Updated On: August 7th, 2017] [Originally Added On: August 7th, 2017]
- New Gene Therapy for Vision Loss Proven Safe in Humans ... [Last Updated On: August 8th, 2017] [Originally Added On: August 8th, 2017]
- Springfield Mom Works to Raise Awareness after Son Diagnosed with Rare Genetic Disorder - KSMU Radio [Last Updated On: August 9th, 2017] [Originally Added On: August 9th, 2017]
- Cancer's Newest Miracle Cure - TIME [Last Updated On: August 10th, 2017] [Originally Added On: August 10th, 2017]
- Families with kids with Jordan's Syndrome meet for study to learn more about rare gene mutation - FOX 5 DC [Last Updated On: August 11th, 2017] [Originally Added On: August 11th, 2017]
- Springfield Mom Works to Raise Awareness after Son Diagnosed with Rare Genetic Disorder - KRCU [Last Updated On: August 11th, 2017] [Originally Added On: August 11th, 2017]
- Exclusive interview with Discovery's First in Human sickle cell ... - Monsters and Critics.com [Last Updated On: August 18th, 2017] [Originally Added On: August 18th, 2017]
- DHK - Representative Chris Walsh, 66, non-Hodgkin lymphoma (a white blood cell cancer), Framingham, with Dr ... - WEEI.com [Last Updated On: August 21st, 2017] [Originally Added On: August 21st, 2017]
- Life Lessons: Next generation testing - WFMZ Allentown [Last Updated On: August 21st, 2017] [Originally Added On: August 21st, 2017]
- Potential therapy for eye condition - WTAJ [Last Updated On: August 21st, 2017] [Originally Added On: August 21st, 2017]
- New 3D-drug screening aims to ease economic burden of rare muscle diseases - Medical Xpress [Last Updated On: August 22nd, 2017] [Originally Added On: August 22nd, 2017]
- Doctor on new cancer treatment: 'genetically engineered, tumor-killing factory' - The Business Journal [Last Updated On: August 23rd, 2017] [Originally Added On: August 23rd, 2017]
- Baltimore 5K Aims to Raise Awareness about Sickle Cell Disease - Afro American [Last Updated On: August 25th, 2017] [Originally Added On: August 25th, 2017]
- Stanford Center Hopes to Take Stem Cell and Gene Therapies to a New Level - Sickle Cell Anemia News [Last Updated On: August 25th, 2017] [Originally Added On: August 25th, 2017]
- Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $11.9 billion - Los Angeles Times [Last Updated On: August 30th, 2017] [Originally Added On: August 30th, 2017]
- Man describes new FDA-approved gene therapy for leukemia that changed his life - fox4kc.com [Last Updated On: September 1st, 2017] [Originally Added On: September 1st, 2017]
- First gene therapy to treat cancer gets FDA approval; UM only Michigan hospital to use it - Detroit Free Press [Last Updated On: September 1st, 2017] [Originally Added On: September 1st, 2017]
- Why the federal government urgently needs to fund more cancer research - Los Angeles Times [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- New 'hit-and-run' gene editing tool temporarily rewrites genetics to treat cancer and HIV - GeekWire [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- UTSA Presidential Lecture featuring Leonard Pinchuk - UTSA Today [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- South Bend man a 'walking miracle' after cancer treatment breakthrough - South Bend Tribune [Last Updated On: September 6th, 2017] [Originally Added On: September 6th, 2017]
- Gene therapy - Doctor.ndtv.com [Last Updated On: May 18th, 2018] [Originally Added On: May 18th, 2018]
- what is gene therapy? - Bluebird Bio [Last Updated On: May 24th, 2018] [Originally Added On: May 24th, 2018]
- Oncotype DX: Genomic Test to Inform Breast Cancer Treatment [Last Updated On: September 29th, 2018] [Originally Added On: September 29th, 2018]
- Gene Therapy: The Future of Vision Treatment [Last Updated On: February 21st, 2019] [Originally Added On: February 21st, 2019]
- Gene Therapy Questions | FAQs - Dana-Farber/Boston ... [Last Updated On: April 22nd, 2019] [Originally Added On: April 22nd, 2019]
- Gene therapy might be a cure for "bubble boy disease ... [Last Updated On: April 24th, 2019] [Originally Added On: April 24th, 2019]
- Xconomy: SMA Moment: Will Gene Therapy Shift Treatment ... [Last Updated On: May 2nd, 2019] [Originally Added On: May 2nd, 2019]
- A Study to Evaluate the Efficacy and Safety of Factor IX ... [Last Updated On: May 26th, 2019] [Originally Added On: May 26th, 2019]
- Targeted Therapy | Treating Mesothelioma - Mesothelioma Hub [Last Updated On: September 26th, 2019] [Originally Added On: September 26th, 2019]
- Why the focus of autism research is shifting away from searching for a 'cure' - NBCNews.com [Last Updated On: September 26th, 2019] [Originally Added On: September 26th, 2019]
- Here's What Happened to Dr. Sharpe on 'New Amsterdam' Details! - Distractify [Last Updated On: September 26th, 2019] [Originally Added On: September 26th, 2019]
- Gene therapy drug priced at $2 million saves North Carolina babys life - WTKR News 3 [Last Updated On: September 26th, 2019] [Originally Added On: September 26th, 2019]
- Pollard and Norris in the race for Pos. 2 of the Public Hospital District 4 - Snoqualmie Valley Record [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Three to be honored as Distinguished Clay High School Alumni - Press Publications Inc. [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Nearly Half of Poland's SMA Patients on Track to Get Spinraza, Experts Say - SMA News Today [Last Updated On: September 30th, 2019] [Originally Added On: September 30th, 2019]
- Genentech to Present Results of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People for... [Last Updated On: October 2nd, 2019] [Originally Added On: October 2nd, 2019]
- Beyonc's father Mathew Knowles has breast cancer: Here's what you need to know about the disease in men - Yahoo Lifestyle [Last Updated On: October 4th, 2019] [Originally Added On: October 4th, 2019]
- Study Measures Prognosis for Breast Cancer Patients with High 21-gene Recurrence Score Receiving Adjuvant Chemotherapy Plus Endocrine Therapy -... [Last Updated On: October 4th, 2019] [Originally Added On: October 4th, 2019]
- Beyoncs father diagnosed with breast cancer - Houston Chronicle [Last Updated On: October 4th, 2019] [Originally Added On: October 4th, 2019]
- What one doctor thinks about drug shortages and how to solve them - STAT [Last Updated On: October 4th, 2019] [Originally Added On: October 4th, 2019]
- The facts about breast cancer awareness | News - The Albany Herald [Last Updated On: October 8th, 2019] [Originally Added On: October 8th, 2019]
- Metastatic Breast Cancer: What You Should Know - University of Michigan Health System News [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
- John Geyman on the Failure of Obamacare the Medical Industrial Complex and the Single Payer Solution - Corporate Crime Reporter [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
- Quebec to cover revolutionary cancer treatment for types of leukemia and non-Hodgkins lymphoma - CTV News [Last Updated On: October 11th, 2019] [Originally Added On: October 11th, 2019]
- Deepak Chopra Has Never Been Sick - The New Yorker [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Daughter drew inspiration from mom in battle with breast cancer, stresses early detection - Gainesville Daily Register [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Cleft palate or lip is one of the most common birth defects worldwide, but do you know what it is? - ABC News [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Pearland family fighting to get $2.1 million drug for toddler with rare genetic disease - KHOU.com [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Gene-Therapy Treatment Could Help People with Macular Degeneration - Healthline [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- A Netflix Series Explores the Brave New World of Crispr - WIRED [Last Updated On: October 18th, 2019] [Originally Added On: October 18th, 2019]
- Save your child from paediatric cancer: Know what to look out for - TheHealthSite [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- The 'Magic' Behind Every Successful Blockbuster Drug - DailyWealth [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- $2.1 million drug approved for Pearland toddler with rare genetic disease - KHOU.com [Last Updated On: October 19th, 2019] [Originally Added On: October 19th, 2019]
- Genentech's Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular... [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- Why Are More Black Women Dying From the Most Common Reproductive Cancer? - Mother Jones [Last Updated On: October 22nd, 2019] [Originally Added On: October 22nd, 2019]
- 5 Biotech and Pharmaceutical Innovation Trends in 2019 - BioSpace [Last Updated On: October 23rd, 2019] [Originally Added On: October 23rd, 2019]